Edesa Biotech Inc (EDSA) Stock Price, Quote & News

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology

Sector: Healthcare

Phone: 289 800 9600

Website: www.edesabiotech.com

Address:

100 Spy Court, Markham, Canada

jrml1957 Mar. 21 at 10:19 PM

$EDSA 10+ next without news.

0 · Reply

EireTrader Mar. 21 at 7:11 PM

$EDSA ... Short interest could be that at the moment

0 · Reply

bachsong Mar. 21 at 6:33 PM

$EDSA With EFFECTIVE FLOAT OF ONLY ... 3.4 Million shares (balance owned by insiders and RECENT institutional investors holding 60% of the stock)... Looking for 10X to 20X "buyout" offer closer to NDA filing... NO DEBT... 2027 CASH RUNWAY... HUGE INSTITUTIONAL and INSIDE OWNERSHIP... $9.43 Major Resistance The 52-week high set on March 20. This is the ultimate "ceiling" to break. $8.00 Psychological Resistance A round number that acted as a pivot point during Friday's session. $7.13 – $7.35 Pivot Zone The current price range (After-hours/Close). Needs to hold here to maintain a bullish bias. $6.88 Immediate Support Friday's intraday low. A break below this could lead to a deeper retracement. $6.50 Structural Support The "Golden Cross" zone and previous breakout ceiling.

1 · Reply

ModernControl Mar. 21 at 6:17 PM

$EDSA biotech, just following along.

0 · Reply

bachsong Mar. 21 at 6:16 PM

$EDSA FLOAT...effectively 3.4 Million shares... NO DEBT! 60% of the 8.35 million shares are held by insiders and long-term funds like Point72 and Perceptive, the actual "tradable" float is only about 3.4 million shares. Institutional Ownership (~41.9%)The institutional base is dominated by top-tier biotech hedge funds that have recently taken significant passive stakes, Major Institutional Holder Ownership Nantahala Capital Management 9.9% Point72 Asset Management (Steven Cohen)7.2% Perceptive Advisors (Joseph Edelman) 6.7% Velan Capital Partners 9.9% Rubric Capital Management 8.2% Insider Ownership (~22.6%) Insiders have been extremely aggressive buyers in 2026, which is a significant signal of confidence in the upcoming regulatory path. Dr. Pardeep Nijhawan (CEO): The largest individual shareholder. He owns approximately 20% of the company. Recent Action: He has been buying shares in the open market.

0 · Reply

lecagot Mar. 20 at 11:34 PM

$EDSA list of the companies. Ajanta Pharma Limited Akorn Operating Company LLC Alembic Pharmaceutical Ltd. Cipla Inc. Indoco Remedies Ltd. Johnson & Johnson Novartis AG Ocular Therapeutix, Inc. Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. Most of those are big companies . Hold your shares

0 · Reply

lecagot Mar. 20 at 11:33 PM

$EDSA The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow from $1.32 billion in 2024 to $2.53 billion by 2033, registering a CAGR of 7.51% from 2025 to 2033. Key factors driving this growth include the rise in chronic respiratory diseases, advancements in oxygen therapy and mechanical ventilation, and increased awareness for early diagnosis and individualized care. Imaging and clinical criteria are vital for ARDS diagnosis, with new medical technologies and heightened healthcare awareness improving patient outcomes. The market faces challenges such as diagnostic complexities and a lack of specific treatments, but ongoing research and technological advancements continue to support its expansion. North America holds the largest market share, with significant contributions from key players like Silence Therapeutics plc, Gilead Sciences Inc., and Terumo Corporation.

0 · Reply

RKLBupupup Mar. 20 at 10:42 PM

$EDSA

0 · Reply

Rmank47 Mar. 20 at 10:22 PM

$EDSA bearish sentiment?? Huh?? Please pull back and look at the 1 month. Then realize what’s on the table regarding presentations through May… RELAX

0 · Reply

GSP Mar. 20 at 7:59 PM

$SPY $ANNA $EDSA $ARTL

0 · Reply

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Feb 13, 2026, 4:20 PM EST - 5 weeks ago

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Dec 12, 2025, 4:20 PM EST - 3 months ago

Edesa Biotech Reports Fiscal Year 2025 Results

Oct 31, 2025, 4:30 PM EDT - 5 months ago

Edesa Biotech Announces Upcoming Conference Schedule

Oct 28, 2025, 7:45 AM EDT - 5 months ago

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Aug 8, 2025, 4:35 PM EDT - 8 months ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

May 14, 2025, 4:15 PM EDT - 11 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Apr 28, 2025, 4:30 PM EDT - 11 months ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Apr 4, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Announces Chief Financial Officer Transition

Feb 14, 2025, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 13, 2025, 7:00 AM EST - 1 year ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Sep 13, 2024, 7:38 PM EDT - 1 year ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Aug 9, 2024, 4:20 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Jun 24, 2024, 8:20 AM EDT - 1 year ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

May 10, 2024, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Apr 2, 2024, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Mar 21, 2024, 4:30 PM EDT - 2 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 7, 2024, 8:45 AM EST - 2 years ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Jan 4, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results

Nov 20, 2023, 4:05 PM EST - 2 years ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 25, 2023, 9:10 AM EDT - 2 years ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 12, 2023, 12:15 PM EDT - 2 years ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:10 PM EDT - 2 years ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 10, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Sep 28, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Aug 9, 2023, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Jul 26, 2023, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 27, 2023, 8:15 AM EDT - 2 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 15, 2023, 8:00 AM EDT - 3 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

May 11, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Edesa Biotech to Participate in Swiss Biotech Day

Apr 4, 2023, 8:45 AM EDT - 3 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Mar 23, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

Mar 15, 2023, 8:10 AM EDT - 3 years ago

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

Feb 10, 2023, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

Feb 1, 2023, 8:15 AM EST - 3 years ago

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Jan 17, 2023, 8:30 AM EST - 3 years ago

Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug

Dec 20, 2022, 8:30 AM EST - 3 years ago

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

Dec 16, 2022, 9:00 AM EST - 3 years ago

Edesa Biotech Reports Fiscal Year 2022 Results

Dec 2, 2022, 8:00 AM EST - 3 years ago

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

Nov 3, 2022, 9:00 AM EDT - 3 years ago

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Sep 30, 2022, 8:00 AM EDT - 3 years ago

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

jrml1957 Mar. 21 at 10:19 PM

$EDSA 10+ next without news.

0 · Reply

EireTrader Mar. 21 at 7:11 PM

$EDSA ... Short interest could be that at the moment

0 · Reply

bachsong Mar. 21 at 6:33 PM

1 · Reply

ModernControl Mar. 21 at 6:17 PM

$EDSA biotech, just following along.

0 · Reply

bachsong Mar. 21 at 6:16 PM

0 · Reply

lecagot Mar. 20 at 11:34 PM

0 · Reply

lecagot Mar. 20 at 11:33 PM

0 · Reply

RKLBupupup Mar. 20 at 10:42 PM

$EDSA

0 · Reply

Rmank47 Mar. 20 at 10:22 PM

$EDSA bearish sentiment?? Huh?? Please pull back and look at the 1 month. Then realize what’s on the table regarding presentations through May… RELAX

0 · Reply

GSP Mar. 20 at 7:59 PM

$SPY $ANNA $EDSA $ARTL

0 · Reply

GSP Mar. 20 at 7:50 PM

Nasty day for $SPY and these were all long ideas we traded today. Stock selection and A+ setups are everything. $ANNA $EDSA $ARTL .

0 · Reply

RKLBupupup Mar. 20 at 7:33 PM

$EDSA Everyone will tell you that they took profits at the highest point ,yet you can make coin trading this while keeping a core position for the mother of all runs that comes with approval, merger,saftey, or buyout news that can still happen anytime.

1 · Reply